Gregory G. Stone

4.9k total citations
111 papers, 3.7k citations indexed

About

Gregory G. Stone is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Gregory G. Stone has authored 111 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Molecular Medicine, 68 papers in Pharmacology and 39 papers in Epidemiology. Recurrent topics in Gregory G. Stone's work include Antibiotic Resistance in Bacteria (79 papers), Antibiotics Pharmacokinetics and Efficacy (66 papers) and Antibiotic Use and Resistance (29 papers). Gregory G. Stone is often cited by papers focused on Antibiotic Resistance in Bacteria (79 papers), Antibiotics Pharmacokinetics and Efficacy (66 papers) and Antibiotic Use and Resistance (29 papers). Gregory G. Stone collaborates with scholars based in United States, United Kingdom and Canada. Gregory G. Stone's co-authors include Krystyna M. Kazmierczak, Daniel F. Sahm, Boudewijn L. M. de Jonge, Robert K. Flamm, Paul Newell, James A. Karlowsky, Patricia A. Bradford, Katrina Yates, Joseph W. Chow and Jie Song and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Gregory G. Stone

111 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory G. Stone United States	34	2.3k	1.6k	992	982	747	111	3.7k
Andrew Walkty Canada	34	2.8k 1.2×	1.9k 1.2×	1.6k 1.6×	877 0.9×	1.0k 1.4×	126	4.7k
Samuel L Aitken United States	27	1.8k 0.8×	1.2k 0.7×	1.3k 1.4×	891 0.9×	884 1.2×	108	3.5k
Brian A. Potoski United States	30	2.4k 1.0×	1.5k 0.9×	1.3k 1.3×	858 0.9×	1.1k 1.4×	55	3.7k
Simone Ambretti Italy	34	2.8k 1.2×	1.4k 0.9×	1.6k 1.6×	946 1.0×	586 0.8×	146	4.3k
Andrea Lay‐Hoon Kwa Singapore	32	1.7k 0.7×	1.1k 0.7×	1.3k 1.3×	946 1.0×	539 0.7×	127	3.4k
Philippe Lagacé‐Wiens Canada	38	2.9k 1.3×	1.8k 1.1×	1.7k 1.7×	922 0.9×	1.3k 1.7×	126	5.3k
Carmen Peña Spain	34	2.6k 1.1×	758 0.5×	1.3k 1.3×	924 0.9×	816 1.1×	63	3.9k
Stephen Hawser United States	34	1.7k 0.8×	925 0.6×	1.3k 1.4×	786 0.8×	1.6k 2.1×	111	4.2k
Carl Urban United States	32	3.0k 1.3×	1.4k 0.9×	1.2k 1.2×	783 0.8×	827 1.1×	94	4.2k
Alexandre Prehn Zavascki Brazil	35	3.5k 1.5×	2.4k 1.5×	1.5k 1.6×	848 0.9×	589 0.8×	116	4.9k

Countries citing papers authored by Gregory G. Stone

Since Specialization

Citations

This map shows the geographic impact of Gregory G. Stone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory G. Stone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory G. Stone more than expected).

Fields of papers citing papers by Gregory G. Stone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory G. Stone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory G. Stone. The network helps show where Gregory G. Stone may publish in the future.

Co-authorship network of co-authors of Gregory G. Stone

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory G. Stone. A scholar is included among the top collaborators of Gregory G. Stone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory G. Stone. Gregory G. Stone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stone, Gregory G., Mark G. Wise, & Eric Utt. (2024). In vitro activity of ceftazidime–avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020. Microbiology Spectrum. 12(3). e0147323–e0147323. 1 indexed citations

Li, H., et al.. (2024). Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021. Antimicrobial Agents and Chemotherapy. 68(10). e0067024–e0067024. 4 indexed citations

Nichols, Wright W., Sushmita D. Lahiri, Patricia A. Bradford, & Gregory G. Stone. (2023). The primary pharmacology of ceftazidime/avibactam: resistancein vitro. Journal of Antimicrobial Chemotherapy. 78(3). 569–585. 5 indexed citations

Bradley, John S., Emmanuel Roilides, Richard D. England, et al.. (2023). 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial. Open Forum Infectious Diseases. 10(Supplement_2). 3 indexed citations

Kiratisin, Pattarachai, Marie Kempf, Gregory G. Stone, & Eric Utt. (2023). Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020. Journal of Global Antimicrobial Resistance. 34. 113–118. 4 indexed citations

Zhuo, Chao, Yijiang Huang, Wenyuan Liu, et al.. (2022). Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial. SHILAP Revista de lepidopterología. 1 indexed citations

Kempf, Marie, Francis F. Arhin, Gregory G. Stone, & Eric Utt. (2022). Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019. Journal of Global Antimicrobial Resistance. 31. 239–247. 7 indexed citations

Stone, Gregory G. & Meredith Hackel. (2022). Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012–2018. Annals of Clinical Microbiology and Antimicrobials. 21(1). 13–13. 3 indexed citations

Piérard, Denis & Gregory G. Stone. (2021). In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections. Journal of Global Antimicrobial Resistance. 26. 4–10. 9 indexed citations

10.

Bae, In‐Gyu & Gregory G. Stone. (2021). In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016–2018). Diagnostic Microbiology and Infectious Disease. 102(1). 115553–115553. 2 indexed citations

11.

Wilcox, Mark H., Jean Li Yan, Pedro González, et al.. (2021). Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials. Infectious Diseases and Therapy. 11(1). 217–230. 3 indexed citations

12.

Rossolini, Gian María & Gregory G. Stone. (2020). Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017). International Journal of Antimicrobial Agents. 56(3). 106111–106111. 18 indexed citations

13.

Karlowsky, James A., Meredith Hackel, Warren Lowman, et al.. (2020). In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015–2018. Journal of Global Antimicrobial Resistance. 24. 249–256. 8 indexed citations

14.

Bradley, John S., Helen Broadhurst, Karen Cheng, et al.. (2019). Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(8). 816–824. 49 indexed citations

15.

Bae, In‐Gyu & Gregory G. Stone. (2019). Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015–2016. Diagnostic Microbiology and Infectious Disease. 95(3). 114843–114843. 16 indexed citations

16.

Wright, James G., et al.. (2019). A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators. Infectious Diseases and Therapy. 8(2). 185–198. 16 indexed citations

17.

Hackel, Meredith, Krystyna M. Kazmierczak, Daryl J. Hoban, et al.. (2016). Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014. Antimicrobial Agents and Chemotherapy. 60(8). 4677–4683. 35 indexed citations

18.

Gu, Yu, Richard F. Clark, Zhenkun Ma, et al.. (2005). Design, synthesis and structure–activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae. Bioorganic & Medicinal Chemistry Letters. 15(10). 2653–2658. 12 indexed citations

19.

Stone, Gregory G.. (1997). PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. Journal of Antimicrobial Chemotherapy. 40(2). 251–256. 15 indexed citations

20.

Stone, Gregory G., Dee Shortridge, Robert K. Flamm, et al.. (1997). PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin. Epidemiology and Infection. 118(2). 119–124. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact